http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9418315-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_edfc44027af57d02fc84fe2aa383fcaa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-57 |
| filingDate | 1994-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65687452236ffe9a8a56bff79891eb8b |
| publicationDate | 1994-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9418315-A1 |
| titleOfInvention | Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis |
| abstract | A method of adjunctive therapy to inhibit reocclusions in a patient, e.g., after thrombolytic therapy or angioplasty, by administering to the patient a bolus of an amount of purified pro-urokinase ('pro-UK') that inhibits the formation of occlusive thrombi without inducing a systemic effect in the patient, the pro-UK is administered after the completion of the thrombolytic treatment and periodically thereafter for the duration of therapy, and becomes incorporated into the platelets of the patient, thereby increasing the T1/2 of the pro-UK in plasma, which is about 7 to 8 minutes, to about 4 to 5 days, and inhibiting reocclusion without inducing a systemic effect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1615612-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1615612-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2180049-A1 |
| priorityDate | 1993-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 118.